Guselkumab demonstrated efficacy for achieving multidomain LDA/remission among patients with PsA and a prior inadequate response to TNF inhibitors.
BRC-002 is an oral botanically-derived cannabinoid agent expected to reduce the pain and comorbidities associated with CRPS. The FDA has granted Orphan Drug designation to BRC-002 (cannabidiol ...
The impact of socioeconomic factors on disease activity in rheumatoid arthritis (RA) varies by academic or safety net hospital setting.
Genicular artery embolization (GEA) is effective and safe for reducing osteoarthritis (OA) symptoms among patients with knee OA that is refractory to conservative therapy.
The prevalence of anxiety and co-occurring anxiety and depression steadily increased between 1985 and 2004 among patients with RA.
A greater percentage of patients with PsA who received deucravacitinib vs placebo achieved minimal disease activity at 16 weeks.
HealthDay News — Inflammatory bowel disease (IBD) in older adults has become a global public health burden, according to a study published in the Jan. 31, 2025, issue of Autoimmunity Reviews.
Naldemedine may be an effective concomitant treatment in patients with cancer who are insufficiently responsive to magnesium oxide therapy for OIC.
The novel migraine-abortive agents lasmiditan, rimegepant, and ubrogepant effectively treated migraine pain in triptan-insufficient responders.
From 2016 to 2021, there was a decrease in cervical cancer deaths among U.S. women aged younger than 25 years.
Deprescribing antihypertensive medication is not associated with the risk for hospitalization for myocardial infarction (MI) or stroke in long-term care residents.
Half of patients with lupus nephritis progress to end stage renal disease (ESKD), which makes identifying predictors imperative.